Sunday, July 24, 2016

In conversation with Dr. Paul Lem

In conversation with Dr. Paul Lem

July 19, 2016 by · Leave a Comment 

Tweet As CEO and a co-founder of Spartan Bioscience, Dr. Paul Lem has led the closely-held company through FDA and Health Canada approval of the Spartan RX CYP2C19 System, a breakthrough technology that provides fast and inexpensive sample-to-result DNA testing. One-in-three people carry genetic mutations and carrying a CYP2C19 mutation can impair drug metabolism. Some […]

Braeburn taking path as pill-free pharma company

Braeburn taking path as pill-free pharma company

July 12, 2016 by · Leave a Comment 

Tweet Closely-held Braeburn Pharmaceuticals, which in late May received FDA approval to market the first ever six-month implant of buprenorphine for opioid dependence, is developing a portfolio of long-acting implants and injectables that improve public health and social cost outcomes associated with drug diversion, misuse and non-compliance. “This is the way of the future,” Behshad […]

Merus Labs moving up the value chain

Merus Labs moving up the value chain

July 5, 2016 by · Leave a Comment 

Tweet After an 18-month company transformation under new CEO, Barry Fishman, Merus Labs International (NASDAQ:MSLI; TSX:MSL) is now ready to in-license new pharmaceutical products, in addition to optimizing existing products and continuing to acquire legacy products that are no longer strategic for major pharmaceutical companies. “Since the fall of 2014, we’ve strengthened the management team […]

Juniper Pharma’s lidocaine vaginal gel data due in Q3

Juniper Pharma’s lidocaine vaginal gel data due in Q3

June 28, 2016 by · Leave a Comment 

Tweet Juniper Pharmaceuticals (NASDAQ:JNP) expects to report results in the third quarter from a Phase 2b clinical trial of its 10% lidocaine bioadhesive vaginal gel, COL-1077, a local anesthetic for pain from minimally invasive outpatient gynecological procedures. “There is no product like it on the market,” Frank Condella, president and CEO, says in an interview […]

Antibe to have Phase 2 pain data by third quarter

Antibe to have Phase 2 pain data by third quarter

June 21, 2016 by · Leave a Comment 

Tweet Antibe Therapeutics (OTCQB:ATBPF; TSX-V:ATE) expects to have data by the third quarter this year from a small Phase 2 study of its naproxen derivative, ATB-346, in patients with osteoarthritis in the knee. “ATB-346 was designed to deliver non-addictive pain relief with significantly less gastrointestinal and cardiovascular damage than is typically associated with the use […]

S1 Biopharma to start Phase 2b study in female HSDD by yearend

S1 Biopharma to start Phase 2b study in female HSDD by yearend

June 14, 2016 by · Leave a Comment 

Tweet Closely-held S1 Biopharma expects to initiate a Phase 2b study at the end of the year with its lead product candidate for female hypoactive sexual desire disorder (HSDD), Lorexys, and a Phase 2a program with a second therapy, Orexa, for male HSDD. “HSDD is characterized by a lack or absence of sexual fantasies and […]

ESSA Pharma takes unique approach to prostate cancer

ESSA Pharma takes unique approach to prostate cancer

June 7, 2016 by · Leave a Comment 

Tweet A marine sponge, Geodia lindgreni, native to Papua New Guinea may hold the key to a new approach in the treatment of prostrate cancer by ESSA Pharma (NASDAQ:EPIX; TSX:EPI). “Our scientific founders from the BC Cancer Agency and the University of British Columbia spent more than a decade conducting the basic biology research, identifying […]

Lipocine advancing pipeline, PDUFA for oral TRT

Lipocine advancing pipeline, PDUFA for oral TRT

May 31, 2016 by · Leave a Comment 

Tweet With a PDUFA date of June 28 for an FDA decision on its oral testosterone replacement therapy (TRT) product candidate, TLANDO, Lipocine’s (NASDAQ:LPCN) next two pipeline product candidates are advancing towards Phase 3 ready status this year. “We have a robust pipeline with a number of key milestones in 2016 besides the decision on […]

Delivra implementing U.S. expansion strategy for topical creams

Delivra implementing U.S. expansion strategy for topical creams

May 24, 2016 by · Leave a Comment 

Tweet The major initiative for Delivra (TSX-V:DVA) in 2016 is to introduce its flagship LivRelief topical pain and nerve creams to the U.S. market, initially through a U.S. web store and Amazon, and then through regional and national retailers, such as Walmart, Walgreens and CVS. “We are launching an aggressive digital campaign shortly, and later […]

ARIAD hopes to launch second oncology drug in early 2017

ARIAD hopes to launch second oncology drug in early 2017

May 17, 2016 by · Leave a Comment 

Tweet ARIAD Pharmaceuticals (NASDAQ:ARIA) is hoping to receive FDA approval to commercialize in early 2017 its second orphan oncology product, brigatinib, for the treatment of certain genetic forms of non-small cell lung cancer. At the end of 2012, the company launched Iclusig (ponatinib) to treat patients with several genetic types of chronic myeloid leukemia. “As […]

Next Page »

Email Newsletters with Constant Contact
Google+